Vistagen expands PH80 global patent portfolio with new migraine treatment patents in four countries

Vistagen Therapeutics, Inc.

New patents for PH80 migraine treatment issued/allowed in Australia, Hong Kong, Japan, and Mexico.
All new patents expected to be in effect until 2040, subject to possible term extensions.
PH80 is a non-systemic, hormone-free investigational pherine nasal spray for menopausal hot flashes and other conditions.
Patents complement previously granted U.S. Patent No. 11,419,881 and EPO Patent No. 3955933 for migraine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.